1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

CLASH OVER POT RESEARCH GETS PERSONAL

  1. Alfa
    CLASH OVER POT RESEARCH GETS PERSONAL


    Vasconcellos' Long-Ago Self-Esteem Panel Is Derided By DEA Lawyer.


    ARLINGTON, Va. - The Bush administration is using hardball and ridicule this week as it fights efforts to expand medical marijuana research.


    Former California legislator John Vasconcellos caught the ridicule, with derisive inquiries into his past work on self-esteem. Others faced hardball, with questions about their pot smoking. It's all part of a high-stakes fight as a reluctant Drug Enforcement Administration reconsiders a researcher's application to grow high-quality pot.


    "We're the only people in America who can't get 10 grams of marijuana,"


    research advocate Rick Doblin testified Wednesday.


    The DEA's administrative law courtroom is far from the limelight, and only about one-quarter of the spectator seats were taken Wednesday afternoon.


    Still, the hearing that's likely to last several more weeks is the most important legal proceeding on the issue since the Supreme Court ruled in June that federal authorities can pursue medical marijuana users in California.


    That 6-3 ruling in Gonzales v. Raich did not overturn the medical marijuana provisions approved in California and other states, but it did expose users to potential federal prosecution.


    It's still unclear how aggressively U.S. Attorney General Alberto Gonzales may pursue medical marijuana users. There's no question, though, that the administration disputes marijuana's potential worth as a medicine. That's what makes the new hearing so crucial, and it may also help explain some of the courtroom tactics.


    After years of delay, the DEA's administrative law judge is being asked to help overturn the agency's rejection of a marijuana researcher's application first filed in 2001. University of Massachusetts plant physiologist Lyle Craker had sought approval to grow 25 pounds.


    "We (look) at marijuana as we would do any other medicinal plant," Craker testified.


    Craker said the limited marijuana now grown under federal supervision at a 12-acre University of Mississippi site is weak and filled with stems and seeds. Craker, the editor of the Journal of Herbs, Spices and Medicinal Plants, said his more potent pot would help test new vaporizers as a healthier means for patients to ingest the smoke.


    The American Civil Liberties Union is supporting Craker's effort, as are several law firms working on a pro bono basis.


    "We're not doing marijuana research because we can't seem to get marijuana," said Doblin, head of the nonprofit Multidisciplinary Association for Psychedelic Studies, "so we're spending money on litigation."


    Drug enforcement officials reply that the University of Mississippi's inventory already contains some 1,500 kilograms of marijuana. Officials say that stash, combined with rolling machines that can crank out 1,000 marijuana cigarettes every minute, can more than meet existing research needs for a drug the government considers dangerous.


    "Marijuana," the DEA said in court filings, "has no currently accepted medical use in treatment in the United States."


    The government's existing marijuana stocks supplied scientists, for instance, at the University of California Medical Cannabis Research Center.


    While in the state Senate, Vasconcellos drafted the bill creating the research center.


    That's why Vasconcellos was called to testify on Craker's behalf this week, but that's not what DEA attorney Imelda Paredes wanted to ask him about.


    Instead, in an apparent effort to undercut the former Democratic legislator's credibility, Paredes pressed Vasconcellos on the California self-esteem task force that finished its work 15 years ago.


    "Haven't research studies shown that in academic terms, self-esteem curricula are worse than useless?" Paredes asked.


    Paredes also noted Vasconcellos' place in a conservative author's book titled "One Hundred People Who Are Screwing Up America."


    Vasconcellos' testimony ended shortly after he defended the self-esteem programs.


    On Wednesday, DEA attorney Brian Bayley took a different tack with Doblin, by pressing him repeatedly about his own marijuana use. Over his lawyer's objections, Doblin acknowledged he had begun smoking marijuana in the early 1970s and still smokes it recreationally about once a week.


    Bayley then asked him who he bought his pot from; at that point, the judge said the DEA had gone far enough.


    The hearing will continue through Friday and then resume next month. The administrative law judge will make a recommendation but cannot order the DEA to grant the application.

Comments

  1. Alfa
    THE RIGHT TO GROW


    A Second Chance For Medical Marijuana


    Dr. Lyle Craker, a professor of plant and soil sciences at UMass Amherst, has been trying since 2001 to get a license from the Drug Enforcement Administration (DEA) to grow research-grade marijuana for use in Food and Drug Administration-approved studies of the plant's potential to become a legally prescribed medicine.


    Last December, after more than three years of stonewalling, the DEA officially rejected his application, holding that his study "would not be consistent with the public interest." (See "Up in Smoke," This Just In, December 17, 2004.)


    Now Craker, along with the Belmont-based Multidisciplinary Association for Psychedelic Studies (MAPS) and the ACLU's Drug Law Reform Project, is challenging that ruling.


    Hearings began in Washington this week before DEA administrative-law judge Mary Ellen Bittner. Supporters hope the proceedings will end the DEA's obstruction and remove the federal government's monopoly on research marijuana.


    In the wake of the Raich v. Ashcroft decision in June, in which the Supreme Court affirmed that federal law supersedes state law in matters of drug enforcement, FDA approval is really the only avenue left for medical marijuana. Before that can happen, there must be studies into its safety and efficacy. "We have considerable lay information about the potential health benefits of this plant material, but we lack the scientific studies that are necessary to prove the value of medicine," Craker told the Phoenix in December.


    "The first step in that is producing quality plant material that will have bioactive constituents in it."


    But at the moment, all marijuana used for research in the US comes from a closely monitored crop maintained by the National Institute on Drug Abuse (NIDA). The complainants in the Craker case maintain that the supply is insufficient, and of inadequate quality, for proper research - let alone for prescription sale should the FDA ever approve it. Moreover, the feds are stingy in distributing the plants.


    MAPS president Rick Doblin says that just last week, NIDA refused to provide 10 grams of marijuana for a MAPS-sponsored vaporizer study at Chemic Labs in Canton.


    Last month, Democratic Massachusetts representatives John Olver and Michael Capuano sent a letter to DEA administrator Karen Tandy, expressing "strong support" for issuing Dr. Craker's license and pointing out that NIDA's monopoly makes little sense since the DEA has licensed privately funded production of other Schedule I drugs, such as MDMA and LSD. (MAPS has funded studies using independently produced MDMA and psilocybin.)


    "The government is basically scared of this research," says Doblin, during a break in testimony. "They want it two ways. They want to say there's not enough research to make marijuana into a medicine, and they want to block the research." Still, he feels reasonably confident that the DEA's decision might be reversed. "My sense is that the judge is fair, she's asking good questions, I have a lot of respect for the way she's interacted with us so far." Time will tell if his optimism is well-founded. There will be another week of testimony toward the end of September, and another (if need be) in December, before Judge Bittner makes a recommendation to the head of the DEA. In the meantime, Doblin will be commenting nightly on the goings-on in Washington at http://www.maps.org/weblogs/rick.
To make a comment simply sign up and become a member!